ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Laboratory tests to support the clinical diagnosis of anaphylaxis

Laboratory tests to support the clinical diagnosis of anaphylaxis
Author:
Lawrence B Schwartz, MD
Section Editor:
John M Kelso, MD
Deputy Editor:
Anna M Feldweg, MD
Literature review current through: May 2024.
This topic last updated: May 05, 2024.

INTRODUCTION — Anaphylaxis is a serious systemic allergic reaction that is rapid in onset and may cause death [1]. The diagnosis of anaphylaxis during the acute event is based on the clinical presentation and either a history of a recent exposure to an offending agent or consideration of spontaneous anaphylaxis [1]. There are no laboratory tests available in an emergency department or clinic setting to confirm a diagnosis of anaphylaxis in real time. (See "Anaphylaxis: Emergency treatment".)

However, laboratory tests in serum, plasma, and possibly urine obtained during or shortly after the acute event can help to support the clinical diagnosis of anaphylaxis. These tests can also help identify anaphylaxis in the presence of other disorders that have overlapping clinical presentations, such as severe asthma, myocardial infarction, postural orthostatic tachycardia syndrome, flushing disorders, or various shock syndromes. In addition, these tests may provide evidence for anaphylaxis as a cause of death.

This topic reviews the laboratory tests that can be used to support the clinical diagnosis of anaphylaxis in both adults and children. These tests are different from those that identify sensitization to the inciting allergen, namely measurements of allergen-specific immunoglobulin E (IgE) and those that identify mast cell disorders, which are reviewed separately. (See "Overview of skin testing for IgE-mediated allergic disease" and "Overview of in vitro allergy tests" and "Anaphylaxis: Confirming the diagnosis and determining the cause(s)", section on 'Testing for allergen cause(s)' and "Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis".)

OVERVIEW — The principal effector cells of systemic anaphylaxis certainly include mast cells and likely basophils. The various pre-formed and newly generated mediators secreted by these cells cause many of the signs and symptoms of systemic anaphylaxis. The pathophysiology of anaphylaxis is reviewed in detail separately. (See "Pathophysiology of anaphylaxis".)

Mediators released during anaphylaxis — Mast cells and basophils degranulate upon activation, releasing pre-formed mediators from intracellular granules into the extracellular environment. Two of the most abundant and best-characterized pre-formed granule mediators are tryptase and histamine. Elevations in tryptase and histamine can sometimes be detected in blood samples obtained shortly after the onset of symptoms. Also, elevated levels of histamine, histamine metabolites (N-methylhistamine and N-methylimidazole acetic acid), the prostaglandin D2 (PGD2) metabolites (11-beta-PGF2-alpha, 2,3-dinor-11-beta-PGF2-alpha, or 2,3,18,19-tetranor-11-beta-PGF2-alpha[PGD-M]) and the leukotriene C4 (LTC4) metabolite (leukotriene E4 [LTE4]), can be measured in urine or, in some cases, in serum or plasma after an anaphylactic event.

Available tests — Assays for the following mediators are available commercially in the United States (table 1):

Tryptase (serum/plasma; detects alpha and beta alleles of mature and protryptases [ie, total tryptase])

Histamine (plasma, urine)

N-methylhistamine (plasma, urine)

11-beta-PGF2-alpha (serum/plasma, urine)

LTE4 (urine)

The histamine metabolite N-methylimidazole acetic acid (urine) is available in some commercial laboratories.

Platelet-activating factor (PAF) [2], PGD2 [3], chymase [4], and mast cell carboxypeptidase A3 in serum are also being investigated in research laboratories as biomarkers of anaphylaxis but require further study [5]. (See 'Possible future tests' below.)

Time course of mediator release — Elevations in tryptase and histamine may be transiently detectable following anaphylaxis:

Total tryptase should be measured 30 to 120 minutes after the onset of anaphylaxis signs or symptoms (table 2), ideally from one to two hours after onset, because most patients have recovered from hypotension by one hour and levels should be at or near peak during the second hour after onset. This level should be compared with one obtained at baseline, which could either be prior to the event (eg, retrieved serum sent to the lab for a different test) or at least 24 hours after all signs and symptoms have resolved. During experimental insect sting anaphylaxis, serum tryptase levels peak 30 to 90 minutes after the onset of symptoms and then decline with a half-life of approximately two hours, so, with a very high peak, levels may remain elevated up to six hours [6,7]. After anaphylaxis to an ingested food, peak tryptase levels are lower than when anaphylaxis is triggered by insect stings or drugs and may be delayed until two hours after onset of symptoms [8]. The larger the initial elevation of tryptase, the longer the level remains elevated above baseline and may do so for several hours after the event. (See 'Tryptase' below.)

Histamine elevations are even more fleeting. Plasma histamine levels peak within 5 to 10 minutes after symptom onset and decline with a half-life of 1 to 2 minutes, such that levels typically return to baseline by 15 to 30 minutes [6,7,9-11]. Therefore, samples should be drawn as soon as possible, preferably 2 to 15 minutes from the onset of symptoms (table 3). Metabolites of histamine are slightly longer lasting in blood and may appear in urine made within 30 to 60 minutes of the event. They remain detectable in urine stored in the bladder for hours. (See 'Histamine' below.)

TRYPTASE — Tryptase is produced by and stored in both mast cells and basophils, although mast cells contain approximately 500-fold more than basophils [12-14]. The biologic functions of tryptase have not been fully defined. Because tryptase is relatively specific for mast cells, acutely elevated tryptase levels in serum or plasma when compared with a baseline level indicate involvement of these cells in clinical events [15].

Immature and mature forms — Mast cell tryptase exists in two alleles (alpha and beta), both of which have mature and immature (pro) forms:

Immature – The vast majority of tryptase measured in serum by a commercial total tryptase assay when a patient is in their normal (basal) state of health (ie, not immediately after an allergic reaction or anaphylaxis) is called a basal or baseline serum tryptase (BST). The BST is predominantly made of the immature forms of tryptase, also known as protryptase. Alpha-protryptase and beta-protryptase are spontaneously secreted by unstimulated mast cells [16].

Mature – Another portion of protryptases is proteolytically processed (at acidic pH and in the presence of heparin) to their mature forms, namely beta-tryptase and alpha-tryptase, which form tetramers that are stored inside the secretory granules of mast cells in a macromolecular complex with heparin proteoglycan [17-21]. When mast cells become activated and degranulate, mature tryptase(s) and histamine are released into the extracellular environment. Baseline serum levels of mature tryptase are normally undetectable (<1 ng/mL) in healthy individuals who have not experienced anaphylaxis in the preceding few hours, and, thus, mature forms of tryptase make up a very small amount of the tryptase in a BST sample.

In vitro potential biologic activities of mature beta-tryptase homotetramers include generation of complement anaphylatoxins and kinins, inactivation of fibrinogen, and stimulation of a variety of different cell types, while its activity(ies) in vivo remains uncertain. Potential biologic activities of alpha/beta-tryptase heterotetramers included activation of protease-activated receptor 2 (PAR2) on a variety of cell types, including endothelial cells that could increase vasopermeability, and cleavage of epidermal growth factor (EGF) like module-containing mucin-like hormone receptor-like 2 (EMR2), making mast cells in skin susceptible to vibration-triggered urticaria [22].

Genetics — The genes for the human alpha- and beta-tryptases reside on chromosome 16. The dimorphic tryptase alpha/beta 1 (TPSAB1) gene can give rise to alpha- or beta-tryptase, and the monomorphic TPSB2 gene only gives rise to beta-tryptase. Humans normally have four functional tryptase genes (two from each parent). In the United States, approximately 25 percent of people have two alpha and two beta genes, approximately 50 percent have one alpha and three beta genes, and the remaining 25 percent have four beta genes, though there are racial variances in these distributions [23]. The prevalence of alpha-tryptase deficiency varies among subjects with Asian (10 percent), European (23 percent), or African (41 percent) ancestry [24]. In contrast, no subject lacking a gene encoding an active form of beta-tryptase has been reported [24].

The normal tryptase genotypes have small effects on the level of total tryptase (ie, <1 ng/mL difference) [25]. In contrast, having extra copies of alpha-tryptase-encoding TPSAB1 markedly increases serum tryptase levels, largely due to an enhancer that is only present in these extra copies [26,27]. This trait is called hereditary alpha-tryptasemia (HaT). On average, each extra copy increases the BST by 9 to 10 ng/mL. To date, this trait is found in five to seven percent of populations with European ancestry, in whom it is the most common cause of an elevated BST level, and is rare in those of Asian or African ancestry. (See 'Hereditary alpha-tryptasemia' below.)

Assays — An enzyme-linked immunosorbent assay (ELISA) for "total" tryptase is commercially available as "ImmunoCAP tryptase" through many commercial laboratories [28]. This assay detects all forms of alpha- and beta-tryptases (mature and pro forms) in combination. It has been approved by the World Health Organization and the US Food and Drug Administration for use in diagnosing systemic mastocytosis (SM) [29]. An ELISA for mature tryptase (alpha and beta) was previously available through the author's laboratory but is no longer.

Proper collection of samples — Serum or plasma for tryptase should be obtained ideally within the first one to three hours after anaphylaxis (table 1). Printable instructions for proper collection and handling of samples for tryptase measurement are provided (table 3). Measurements of tryptase in serum and plasma are similar [30]. An additional sample should be collected at least 24 hours after all signs and symptoms have resolved to serve as a baseline sample for comparison. Frozen serum or plasma obtained before the event can also be used as a baseline and is often available for hospitalized patients. Tryptase is stable in frozen serum for at least one year.

Most laboratories require 1 mL of serum (red top tube) or plasma (heparin, citrate, or ethylenediaminetetraacetic acid [EDTA]). Serum and plasma tryptase levels are similar [30]. If not processed on site, the sample should optimally be frozen and can be stored at -20 or -80⁰C for up to several years. Once the samples are thawed, they should be measured within 12 hours. It may also be refrigerated for approximately one week. Samples left at room temperature for more than one or two days might yield falsely low values. Serum or plasma for tryptase measurements should be shipped frozen by overnight courier.

For postmortem samples, collection from the femoral artery or vein rather than the heart is recommended to minimize the contribution of nonspecifically released tryptase from mast cells in disintegrating or traumatized cardiac tissue [31].

Normal levels — Baseline serum total tryptase (BST) levels range from 1 to 11.4 ng/mL with an average of 3 to 5 ng/mL (table 2). In 204 individuals without HaT, kidney failure, or a clonal myeloid disorder, the median BST level was 4.2 ng/mL, and the upper limit of the 99.9 percent prediction interval was 11.4 ng/mL [27]. Accordingly, 11.4 ng/mL can continue to be used to determine whether a further workup for an elevated tryptase level in an otherwise healthy patient without HaT or kidney failure should be performed to detect an underlying clonal mast cell disorder.

Based on limited data, mean BST levels in infancy may be slightly higher than those in older children and adults, although still within the normal range [32]. The primary determinant of the BST level is genetic [33]. BST levels for a specific individual are very consistent over time, but there may be more variability in people with HaT or SM.

In patients with HaT — If hereditary alpha-tryptasemia (HaT) is present, higher cutoffs have been recommended to help determine whether a further workup for a clonal mast cell disorder is indicated:

36 ng/mL for HaT with one copy number variant (CNV) of TPSAB1

62 ng/mL for two CNVs

89 ng/mL for three CNVs

Levels may also be calculated via a calculator provided on the National Institutes of Health (NIH) website.

If testing for HaT is not available, an expert panel met in 2022 and recommended that the upper limit of 11.4 ng/mL should be adjusted upwards to 15 ng/mL to account for many, although not all, of the HaT cases in the general population who are otherwise in good health [34]. HaT is reviewed in greater detail elsewhere. (See 'Hereditary alpha-tryptasemia' below and "Hereditary alpha-tryptasemia".)

Elevations in anaphylaxis — Elevated levels of total tryptase in serum or plasma may be useful for distinguishing anaphylaxis from other conditions in the differential diagnosis, such as vasovagal reactions, septic shock, seizures, myocardial shock, benign flushing, or carcinoid syndrome. These other disorders are not normally associated with acute elevations in serum total tryptase levels (personal experience of author). (See "Differential diagnosis of anaphylaxis in adults and children".)

The following observations have been made about tryptase elevations with anaphylaxis:

Tryptase levels in serum or plasma begin to rise as early as five minutes after clinical onset of anaphylaxis, reaching maximal levels between 30 and 120 minutes, and then decline with a half-life of approximately two hours.

Elevations can range from marginally elevated to levels >100 ng/mL. Dramatic elevations have been recorded following anaphylactic shock induced by medications, for example.

Elevations correlate well with hypotension but not as well with cutaneous, respiratory, or gastrointestinal signs or symptoms [6].

The specificity and sensitivity of tryptase elevations have not been precisely determined but increase with clinical severity.

Between-assay variability can be eliminated if both acute and baseline samples are assayed simultaneously.

Interpretation of total tryptase — Following the widespread activation of mast cells (and possibly basophils) that occurs during anaphylaxis, mature tryptase is released, and the total serum tryptase may increase as a result.

The minimal elevation of the acute total tryptase level that is considered to be clinically significant was suggested to be ≥(2 + 1.2 x baseline tryptase levels) in units of ng/mL or mcg/liter [35]. Note that mast cell activation can be detected using this equation, even when the acute tryptase level is in the normal range [36,37]. The value of the acute versus baseline formula above was shown to have a high positive predictive value and moderate negative predictive value, depending on clinical severity, in perioperative [38] and emergency department [3] settings.

Comparing acute and baseline levels greatly improves the diagnostic value of total tryptase measurements. If total tryptase is the only test available, then paired levels are essential for interpretation (table 4).

Higher baseline levels of total tryptase initially appeared to increase the risk for more severe anaphylaxis, particularly in insect venom-sensitive subjects, to both field stings and venom immunotherapy [39,40]. However, this risk may reflect the increased likelihood of underlying mastocytosis, an activating c-kit mutation, and/or the HaT genetic trait rather than an effect of the tryptase level per se. Notably, patients with a history of systemic anaphylaxis to insect stings and a baseline tryptase level >5 ng/mL have a high prevalence of underlying clonal mast cell disease (SM or monoclonal mast cell activation syndrome [MMAS]) and/or HaT [41-45]. This possibility should be considered in any patient with hypotensive reactions to insect stings. (See "Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Recurrent severe anaphylactic episodes'.)

Relationship to hypotension — During insect sting-induced anaphylaxis, which has been more extensively studied than other causes of anaphylaxis, the magnitude of the serum tryptase elevation correlates closely with the drop in mean arterial pressure but not with the severity of cutaneous, gastrointestinal, or respiratory symptoms, indicating that the magnitude of mast cell activation is a primary determinant of the severity of this clinical manifestation [9,30]. In the absence of hypotension, there may not be sufficient release of tryptase that enters the circulation to raise serum or plasma levels. So, the absence of a significant rise in the acute tryptase level does not rule out local mast cell activation.

Food-induced anaphylaxis — Elevated levels of total tryptase during acute clinical events implicate mast cell involvement. However, total tryptase levels are less often elevated in food-induced than in insect sting-triggered anaphylaxis [46,47], although elevations are often seen in cases of food-induced anaphylactic fatalities [47]. However, utilizing the acute ≥(2 + 1.2 x baseline tryptase level) formula allows identification of a clinically significant rise in the tryptase level, even when the acute level is <11.4 ng/mL [48]. Also, the peak level may be delayed until two hours after symptom onset with food-triggered anaphylaxis [8]. Several possible explanations for lower or no tryptase elevation in food-induced anaphylaxis have been proposed, including the following:

Localized rather than systemic release of mast cell mediators may occur in some victims of anaphylaxis (eg, those with laryngeal edema).

Tryptase released by mast cells at mucosal sites may not diffuse into the circulation as efficiently as that released near blood vessels, and mast cells at mucosal surfaces contain less tryptase than those in the skin and perivascular tissues.

There may be IgE-dependent anaphylactic pathways that bypass mast cells and involve basophils and/or other cell types. However, proving basophils are involved in anaphylaxis has been problematic because there is no serum or plasma biomarker for specifically detecting basophil activation.

Other pathways that could clinically mimic anaphylaxis might include production of nonmast cell vasoactive mediators, such as complement anaphylatoxins (C3a and C5a), kinins, or lipids. (See "Pathophysiology of anaphylaxis".)

Fatal anaphylaxis — A study of total tryptase levels in postmortem sera suggests that a total tryptase level >45 ng/mL is consistent with systemic anaphylaxis near the time of death [49], but this might be problematic in the absence of a baseline tryptase level. The etiology and pathogenesis of fatal anaphylaxis are reviewed in more detail separately. (See "Fatal anaphylaxis".)

Diagnostic specificity of postmortem levels — Given the lack of a gold standard for identifying death from anaphylaxis, it is hard to know when an elevated tryptase level indicates mast cell activation near the time of death or is a false positive. The diagnostic specificity of postmortem tryptase levels has been challenged by a study that found elevated levels of mature tryptase in approximately 10 percent (5 of 49) of fatalities believed to be nonanaphylactic [50]. In the five patients with postmortem tryptase levels >10 ng/mL:

One death was attributed to salicylate overdose, although aspirin sensitivity could have coexisted and caused mast cell activation [50]. Mast cell activation has been well documented in aspirin-sensitive subjects challenged with aspirin-like drugs [51-54].

Another death was associated with atherosclerotic coronary vascular disease, although details were not available regarding drugs received near the time of death that could have activated mast cells, such as morphine.

The remaining three individuals died of trauma, and, although there are few studies on serum tryptase elevations in trauma patients, elevated tryptase levels in peritoneal lavage fluids have been noted in patients following intestinal manipulation during abdominal surgery [55].

In another postmortem study, total tryptase levels in aortic serum in excess of 110 ng/mL had a sensitivity of 80 percent and specificity of 92 percent for fatal anaphylaxis [56], and, in a subsequent study, levels above 43 ng/mL had a sensitivity of 90 percent and specificity of 98 percent [57]. However, the cause of an elevated postmortem tryptase is not precisely understood, such as leakage of tryptase from dead or dying mast cells into periaortic tissues and then into blood. Therefore, this remains an area in need of further study.

Elevations of tryptase in nonanaphylactic patients — The levels of total tryptase in nonanaphylactic subjects are largely composed of immature protryptases and reflect (in part) the total body burden of mast cells.

Systemic mastocytosis — Total tryptase is elevated (>20 ng/mL) in most patients with SM, a disorder of clonal mast cell hyperplasia (table 2). A total tryptase level >20 ng/mL in the absence of another cause for an elevated level is just one of the four World Health Organization minor criteria for diagnosis [58]. SM or related monoclonal mast cell activation disorder, both having gain-of-function mutations in the gene encoding Kit, may present with spontaneous, insect sting-induced, or allergen-induced anaphylaxis [59]. The diagnosis of SM is reviewed in detail separately. (See "Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis" and "Mastocytosis (cutaneous and systemic) in children: Epidemiology, clinical manifestations, evaluation, and diagnosis".)

Hereditary disorders associated with mast cell activation

Hereditary alpha-tryptasemia — HaT is an autosomal dominant genetic condition in which affected members have high normal or elevated baseline total tryptase levels (>8 ng/mL) [60]. The prevalence of HaT in the general population may be as high as 6 percent in those with European ancestry, among whom it is the most common reason for a baseline total tryptase greater than 15 ng/mL.

HaT can also coexist with clonal mast cell disease [61]. In patients with SM, the presence of concomitant HaT is associated with a higher risk of insect venom-triggered or of spontaneous anaphylaxis than observed for either disorder by itself [62]. HaT is present in approximately 13 percent of European patients with mastocytosis, approximately 20 percent with bone marrow SM, and approximately 33 percent with monoclonal mast cell activation syndrome [44,45]. HaT is also more prevalent in patients with idiopathic anaphylaxis. (See "Hereditary alpha-tryptasemia".)

Other genetic conditions — Other genetic conditions associated with mast cell activation have been reported, although these have not been associated with elevations in baseline tryptase:

Two families with vibratory urticaria were found to have an autosomal dominant gain-of-function mutation in the gene ADGRE2, which encodes the EMR2 receptor [63]. Mast cells derived from these individuals demonstrated vibration-dependent degranulation in vitro.

Individuals with familial periodic fever syndromes associated with gain-of-function mutations in cryopyrin (familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disorder) had a positive cutaneous ice cube challenge test and mast cells that were activated ex vivo by cold temperatures to secrete interleukin 1-beta [64,65].

An autosomal dominant inborn error of immunity (also known as a primary immunodeficiency) caused by a gain-of-function mutation in phospholipase C-gamma-2 results in urticaria during evaporative cooling of the skin and mast cells activated ex vivo by cool temperatures [66].

Poorly controlled Gaucher disease [67]. (See "Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis".)

Other conditions — Elevated baseline total tryptase levels are also observed in the following disorders:

Acute myeloid leukemia [68] (see "Acute myeloid leukemia: Clinical manifestations, pathologic features, and diagnosis")

Chronic myeloid leukemia (CML; chronic or accelerated phase) [34]

Chronic eosinophilic leukemia (CEL) [34]

Myelodysplastic syndromes [69] (see "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)")

The myeloid variants of hypereosinophilic syndrome (particularly those associated with the Fip1-like1-platelet-derived growth factor receptor alpha [FIP1L1-PDGFRA] mutation) [70] (see "Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis")

Severe kidney failure (ie, chronic kidney disease stages 4 and 5 and patients on hemodialysis) [71-73]

GATA-2 haploinsufficiency [74]

With the treatment of onchocerciasis, though whether this reflected mast cell activation, disruption, or hyperplasia was not clear [75] (see "Onchocerciasis")

After administration of recombinant stem cell factor due to mast cell hyperplasia [76] (see "Introduction to recombinant hematopoietic growth factors", section on 'Stem cell factor and Flt3 ligand')

Causes of false-positive elevations — False elevations in tryptase levels, though uncommon [77], have been associated with the presence of heterophilic antibodies (ie, usually human antimouse antibodies) in a patient's serum [78-80]. Such antibodies are more likely in patients who have received the chimeric (mouse Fab/human Fc) antibody infliximab or who test positive for rheumatoid factor. However, since the mouse IgG anti-tryptase detector antibody was modified to the F(ab′)2 fragment by removing the Fc portion (2015 in Europe; 2018 in the US) [81], this problem appears to no longer be an issue.

HISTAMINE — Histamine is a biogenic amine produced by and stored primarily in human mast cells and basophils, which produce comparable amounts of histamine [14]. Histamine may also be produced and secreted by activated neutrophils, monocytes, T lymphocytes, keratinocytes, and enterochromaffin cells that express histidine decarboxylase [82,83] but do not store it. Histamine is the only pre-formed granule mediator in all mast cells and basophils known to have direct potent vasoactive and smooth muscle spasmogenic activities. Pre-formed alpha/beta-tryptase heterotetramers, by activating protease-activated receptor 2 (PAR2) on the surface of endothelial and smooth muscle cells, may also contribute to overlapping manifestations, as do newly generated mediators such as prostaglandin D2 (PGD2), leukotriene C4 (LTC4), and platelet activating factor (PAF).

Histamine is generated intracellularly from histidine by histidine decarboxylase. Most of this histamine is then stored in the secretory granules of mast cells and basophils, although a small portion is released constitutively. Histamine binds to carboxyl and possibly sulfate moieties on proteins and proteoglycans in the acidic pH environment of secretory granules. However, in the neutral pH of the extracellular environment, histamine is less positively charged and becomes dissociated from the macromolecular structures to which it had been bound. Free histamine has low molecular mass (111 Da) and high solubility and rapidly diffuses away from its local sites of release. A portion may enter the circulation. A smaller amount of free histamine may pass into the urine unmetabolized.

Elevations during anaphylaxis — Similar to tryptase, any elevation in plasma or urine histamine is consistent with anaphylaxis, although normal levels do not exclude the diagnosis. Ideally, the acute level should be compared with a baseline level.

Histamine elevations correlate well with clinical severity of anaphylaxis. Although histamine levels in properly collected samples of plasma have a greater sensitivity than tryptase, the short plasma half-life of histamine and the difficulties in handling the sample usually limit the utility of this measurement in the clinical setting [84].

Histamine metabolites — Within minutes, the majority of released histamine is sequentially metabolized to N-methylhistamine and then to N-methylimidazole acetic acid by histamine N-methyltransferase and monoamine oxidase or to imidazole acetic acid by diamine oxidase. N-methylhistamine and N-methylimidazole acetic acid are specific metabolites of histamine, while imidazole acetic acid is not. Levels of N-methylhistamine or N-methylimidazole acetic acid, which can be measured in plasma or urine, may also reflect overall levels of released histamine. These metabolites, generated acutely and then stored in the bladder, will be detectable in the urine for several hours after anaphylaxis. Elevated urinary N-methylhistamine was observed in specimens collected six hours after an insect sting challenge in patients experiencing systemic anaphylactic symptoms [85].

Some investigators consider these metabolites to be more reliable indicators of histamine release than histamine itself. N-methylhistamine is longer-lived than histamine in the circulation, accounts for a greater portion of the released histamine that ends up in the urine, and demonstrates less natural diurnal variation [86-88]. However, another study of anaphylaxis during anesthesia found urinary N-methylhistamine to be less sensitive than either plasma tryptase or histamine, so the relative merits of histamine and its metabolites are not fully defined [89].

In summary, urinary histamine, N-methylhistamine, or N-methylimidazole acetic acid levels are helpful when elevated above baseline, but normal levels do not exclude mast cell activation.

Assays and collection of samples — Assays are commercially available to measure histamine and its metabolites in biologic fluids (table 1).

Blood – Normal levels of histamine in plasma are <617 pg/mL (<5.6 nM, Mayo Clinic Laboratory). Plasma should be used, rather than serum, to avoid the artifactual release of histamine from basophils that can occur during clotting. The blood sample should be collected through a 20-gauge or larger needle and pulled manually under gentle pressure into a syringe containing either citrate or ethylenediaminetetraacetic acid (EDTA). Pulling blood through a narrow-bore needle under vacuum can also cause basophil activation or breakage ex vivo and falsely elevate the levels of histamine. Collected anticoagulated blood should be placed on ice and centrifuged to separate plasma from cells as soon as possible and then frozen until ready to be analyzed. Printable instructions for collection and handling are provided (table 3).

Urine – Urine for measuring levels of N-methylhistamine are collected with a standard 24-hour or random collection. Collection of "acute" urine (ie, urine produced during the acute event and stored in the bladder) should begin as soon as possible after the acute event. Normal levels are determined by the specific laboratory that performs the test. Ideally, a second baseline sample should be collected beginning at least 24 hours after all signs and symptoms of anaphylaxis have ceased. Instructions for collecting, storing, and shipping urine specimens can be found on the websites of commercial laboratories [90].

Other causes of elevated histamine — Elevations in plasma or urinary histamine may result from the following:

Scombroidosis, an illness that results from the ingestion of improperly stored fish that has accumulated high histamine levels, presents with flushing, headache, and widened pulse pressure but not with pruritic urticaria and hypotension as seen in systemic anaphylaxis [91]. Often several people eating the same fish are affected. Urinary and plasma histamine or histamine metabolite levels can be elevated, although tryptase levels are normal. Elevated histamine levels are not found in other forms of food poisoning. The diagnosis of scombroidosis is reviewed in more detail separately. (See "Seafood allergies: Fish and shellfish", section on 'Differential diagnosis'.)

Levels of histamine may be elevated in adults with systemic mastocytosis. (See "Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis".)

Urinary histamine and its metabolites may be elevated due to the presence of histamine-producing bacteria in the urogenital or gastrointestinal tracts, although this has not been extensively studied [92].

Histamine-rich foods include some fish, aged cheeses, chocolate, red wine, and vegetables, such as eggplant, spinach, and tomatoes, although the relationship between the histamine content in foods and the appearance of that histamine or its metabolites in the circulation or urine is uncertain, in part because the factors affecting absorption of ingested histamine are unclear [93,94].

Constitutive hyperhistaminemia has been considered as a contributing factor to recurrent anaphylaxis, though convincing data have not emerged [95].

PROSTAGLANDIN AND METABOLITES — Prostaglandin D2 (PGD2) is the principal cyclooxygenase product produced by activated mast cells but is not produced by activated basophils. Antigen-presenting cells, megakaryocytes, T helper type 2 (Th2) lymphocytes, eosinophils, and platelets are also capable of producing this prostaglandin [96]. PGD2 plays a large role in the hemodynamic changes that accompany episodes of systemic mast cell activation [97,98]. Like histamine, clearance from the systemic circulation is rapid, and elevated serum levels of PGD2 are generally difficult to detect [7]. Elevations of the major circulating and excreted metabolite (2,3-dinor-11-beta-PGF2 alpha) can be measured in 24-hour or random acute urine and normalized to urinary creatinine, where it may be a more sensitive indicator of mast cell activation than N-methylhistamine [99-103]. Urinary prostaglandin is available through a limited number of commercial laboratories [104]. A subsequent study reported that plasma levels of 11-beta-PGF2 alpha measured within two hours of an anaphylactic event may be more sensitive than tryptase and leukotriene E4 (LTE4) [3], though additional studies are warranted, particularly regarding specificity.

Measurement of PGD2 or its metabolites is not useful in patients receiving cyclooxygenase inhibitors, including aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs), as these medications block the synthesis of this mediator. (See "NSAIDs (including aspirin): Pharmacology and mechanism of action".)

LEUKOTRIENES AND METABOLITES — Leukotriene C4 (LTC4) is the principal 5-lipoxygenase product produced by activated mast cells and basophils. Activated eosinophils along with certain phagocytic mononuclear cells, endothelial cells, vascular smooth muscle cells, and platelets also can produce this metabolite. Like histamine and prostaglandin D2 (PGD2), it is rapidly metabolized to LTD4 and then to LTE4, which can be measured in urine, a test available commercially in the United States [104]. Although the cell source may be uncertain, elevated LTE4 levels may be seen in the urine after anaphylaxis. In one study, urine LTE4 appeared to discriminate better between systemic anaphylaxis, bronchial asthma, and healthy controls than either urinary 11-beta-PGF2-alpha or serum tryptase [105]. LTE4 also has been measured in plasma, where it seems to be less sensitive than the PGD2 metabolite or tryptase [3]. Each commercial laboratory determines their own normal ranges for these assays.

POSSIBLE FUTURE TESTS — Chymase, mast cell carboxypeptidase A3, and platelet-activating factor are other products that have been evaluated as possible markers of anaphylaxis. Assays for these mediators are not widely available commercially, although they are performed in research laboratories.

Chymase and carboxypeptidase A3 — Chymase and carboxypeptidase A3 are mast cell-derived proteases that are expressed by a subset of mast cells called MCTC (mast cells containing tryptase and chymase), which are the predominant type of mast cells in skin, perivascular tissue, heart, conjunctiva, and bowel submucosa [106]. Chymase and carboxypeptidase A3 are stored in secretory granules and are released from mast cells as a macromolecular protease:proteoglycan complex [21]. Subtypes of mast cells are reviewed in more detail separately. (See "Mast cells: Development, identification, and physiologic roles".)

These proteases are not expressed by basophils:

Chymase levels measured by enzyme-linked immunosorbent assay (ELISA) in postmortem serum were elevated (>3 ng/mL) in fatal anaphylaxis, correlated with elevated levels of tryptase, and were undetectable in most cases of nonanaphylactic deaths [4]. Further evaluation of this potential biomarker of anaphylaxis is needed.

Carboxypeptidase A3 levels measured by an ELISA were elevated (>14 ng/mL) in serum obtained from individuals with a clinical diagnosis of anaphylaxis but not in healthy controls or those with asthma or atopy [107,108]. However, carboxypeptidase A3 and total tryptase levels did not correlate with one another, perhaps because of delayed diffusion of carboxypeptidase A3 into the circulation. Further studies of this potential biomarker are needed.

PLATELET-ACTIVATING FACTOR — Platelet-activating factor (PAF) is generated during anaphylactic reactions to foods [109,110] and perhaps other types of anaphylaxis but also during stroke, sepsis, myocardial infarction, and colitis, limiting its discriminatory ability as a biomarker. Although PAF undergoes rapid metabolism, plasma levels measured after food-triggered anaphylaxis correlate with clinical severity. Also, low levels of serum PAF acetylhydrolase, the enzyme that metabolizes and inactivates PAF, appear to increase risk for more severe anaphylaxis. The enzyme resides on lipid particles in the circulation, and its concentration also relates directly to the concentration of these lipid particles, which is modulated after food ingestion and decreases in response to statins [110].

TESTS FOR CONDITIONS MIMICKING ANAPHYLAXIS — Anaphylaxis can be difficult to distinguish from other medical conditions that mimic signs or symptoms of anaphylaxis, particularly in the absence of an inciting allergen. For example, flushing occurs with carcinoid syndrome, tumors secreting vasoactive intestinal protein (VIPomas), pheochromocytomas, and with activation of the complement or kinin pathways, leading to production of complement C3a, C5a, anaphylatoxins, or bradykinin. To help distinguish these entities from anaphylaxis, several laboratory tests should be considered when clinically appropriate (table 5):

Plasma-free metanephrine and urinary vanillylmandelic acid are elevated in pheochromocytoma. (See "Clinical presentation and diagnosis of pheochromocytoma".)

Serum serotonin and urinary-5-hydroxyindoleacetic acid may be elevated in carcinoid syndrome. (See "Diagnosis of carcinoid syndrome and tumor localization".)

Pancreastatin, vasoactive intestinal peptide, substance P, neurokinin, and/or calcitonin may be elevated in gastrointestinal VIPomas or medullary carcinoma of the thyroid. (See "VIPoma: Clinical manifestations, diagnosis, and management" and "Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging".)

Plasma kallikrein is activated in plasma with activation of the contact pathway (eg, as occurs in patients with C1 inhibitor deficiency or as occurred with heparin preparations contaminated with over-sulfated chondroitin sulfate) [111].

Complement activation with production of anaphylatoxins C3a and C5a may occur after exposure to polyethylene glycol, snake venoms, older dialysis membranes, and nanoparticles [112-115].

The differential diagnosis of anaphylaxis is reviewed separately. (See "Differential diagnosis of anaphylaxis in adults and children".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Anaphylaxis".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Beyond the Basics topics (see "Patient education: Anaphylaxis symptoms and diagnosis (Beyond the Basics)" and "Patient education: Anaphylaxis treatment and prevention of recurrences (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Laboratory tests can support the clinical diagnosis of anaphylaxis – The diagnosis of anaphylaxis is made clinically, and there are no laboratory tests available in an emergency department or clinic setting to verify a diagnosis of anaphylaxis in real time. However, serum, plasma, and urine obtained during or shortly after the acute event can support the clinical diagnosis of anaphylaxis.

Available assays for mast cell and basophil mediators – Mast cells and basophils are the principal effector cells of systemic anaphylaxis and release a variety of mediators upon activation. Assays for tryptase (in serum or plasma), histamine (plasma), histamine metabolites (urine), prostaglandin D2 (PGD2) or its metabolite prostaglandin F2-alpha (PGF2-alpha; urine or plasma), and leukotriene E4 (LTE4; urine or plasma) are available commercially (table 1). Elevations in tryptase correlate with the presence of hypotension and support the diagnosis of anaphylaxis, although normal levels do not exclude anaphylaxis. (See 'Overview' above.)

Timing and collection of samples – Collection of blood for tryptase measurements should be considered if the diagnosis of anaphylaxis is being entertained. Tryptase should ideally be measured within 30 to 120 minutes after onset of anaphylaxis symptoms, but elevations may still be detectable several hours after a severe reaction (table 3). Plasma histamine levels should be measured preferably less than 30 minutes after symptom onset. Metabolites of histamine in urine accumulating over hours may remain elevated for several hours after an anaphylactic event. (See 'Time course of mediator release' above.)

Formula for a clinically significant increase in tryptase – When total tryptase is measured immediately after anaphylaxis, a baseline sample, collected either before the event or at least 24 hours after resolution of the event, is required to interpret total tryptase accurately (table 4). The minimal elevation of an acute total tryptase level that is considered to be clinically significant (ie, indicative of mast cell activation) is a value greater than or equal to (2 + 1.2 × baseline tryptase levels) in ng/mL. (See 'Interpretation of total tryptase' above.)

Histamine and other mediators – Acute plasma histamine elevations correlate well with clinical severity of anaphylaxis, although elevations are fleeting, and blood samples must be handled with great care, limiting the practical utility of this test (table 3). (See 'Histamine' above.)

Urinary metabolites of histamine, such as N-methylhistamine, are longer-lasting and can be assayed in a routine 24-hour urine sample. Like tryptase, any elevations of these mediators collected during the acute over baseline levels support the diagnosis of anaphylaxis, but normal levels do not exclude the possibility of anaphylaxis. (See 'Histamine metabolites' above.)

Urinary PGF2-alpha, a metabolite of PGD2, is elevated after mast cell-mediated anaphylaxis, unless the patient has taken a cyclooxygenase inhibitor, such as aspirin, and can be measured in the same urine specimen as N-methylhistamine. Assays for urinary LTE4 are available from commercial laboratories. (See 'Prostaglandin and metabolites' above and 'Leukotrienes and metabolites' above.)

Other causes of tryptase elevations – Conditions that cause elevated baseline levels of tryptase include hereditary alpha-tryptasemia (HaT), systemic mastocytosis (SM), acute myeloid leukemia, myelodysplastic syndromes, hypereosinophilic syndrome (myeloid variant), Gaucher disease, kidney failure, and onchocerciasis (during active treatment). (See 'Elevations of tryptase in nonanaphylactic patients' above.)

Tests for conditions that mimic anaphylaxis – Several other laboratory tests are useful in excluding rare disorders that can mimic anaphylaxis (table 5). (See 'Tests for conditions mimicking anaphylaxis' above.)

  1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.
  2. Gill P, Jindal NL, Jagdis A, Vadas P. Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis. J Allergy Clin Immunol 2015; 135:1424.
  3. Nassiri M, Eckermann O, Babina M, et al. Serum levels of 9α,11β-PGF2 and cysteinyl leukotrienes are useful biomarkers of anaphylaxis. J Allergy Clin Immunol 2016; 137:312.
  4. Nishio H, Takai S, Miyazaki M, et al. Usefulness of serum mast cell-specific chymase levels for postmortem diagnosis of anaphylaxis. Int J Legal Med 2005; 119:331.
  5. Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2.
  6. Schwartz LB, Yunginger JW, Miller J, et al. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989; 83:1551.
  7. van der Linden PW, Hack CE, Poortman J, et al. Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation. J Allergy Clin Immunol 1992; 90:110.
  8. Dua S, Dowey J, Foley L, et al. Diagnostic Value of Tryptase in Food Allergic Reactions: A Prospective Study of 160 Adult Peanut Challenges. J Allergy Clin Immunol Pract 2018; 6:1692.
  9. van der Linden PW, Struyvenberg A, Kraaijenhagen RJ, et al. Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann Intern Med 1993; 118:161.
  10. Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66:1072.
  11. Halmerbauer G, Hauk P, Forster J, et al. In vivo histamine release during the first minutes after deliberate sting challenges correlates with the severity of allergic symptoms. Pediatr Allergy Immunol 1999; 10:53.
  12. Castells MC, Irani AM, Schwartz LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987; 138:2184.
  13. Jogie-Brahim S, Min HK, Fukuoka Y, et al. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol 2004; 113:1086.
  14. Schwartz LB, Irani AM, Roller K, et al. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987; 138:2611.
  15. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451.
  16. Schwartz LB, Min HK, Ren S, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol 2003; 170:5667.
  17. Le QT, Min HK, Xia HZ, et al. Promiscuous processing of human alphabeta-protryptases by cathepsins L, B, and C. J Immunol 2011; 186:7136.
  18. Le QT, Gomez G, Zhao W, et al. Processing of human protryptase in mast cells involves cathepsins L, B, and C. J Immunol 2011; 187:1912.
  19. Pereira PJ, Bergner A, Macedo-Ribeiro S, et al. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Nature 1998; 392:306.
  20. Schwartz LB, Bradford TR. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J Biol Chem 1986; 261:7372.
  21. Goldstein SM, Leong J, Schwartz LB, Cooke D. Protease composition of exocytosed human skin mast cell protease-proteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. J Immunol 1992; 148:2475.
  22. Le QT, Lyons JJ, Naranjo AN, et al. Impact of naturally forming human α/β-tryptase heterotetramers in the pathogenesis of hereditary α-tryptasemia. J Exp Med 2019; 216:2348.
  23. Soto D, Malmsten C, Blount JL, et al. Genetic deficiency of human mast cell alpha-tryptase. Clin Exp Allergy 2002; 32:1000.
  24. Trivedi NN, Tamraz B, Chu C, et al. Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. J Allergy Clin Immunol 2009; 124:1099.
  25. Min HK, Moxley G, Neale MC, Schwartz LB. Effect of sex and haplotype on plasma tryptase levels in healthy adults. J Allergy Clin Immunol 2004; 114:48.
  26. Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016; 48:1564.
  27. Chovanec J, Tunc I, Hughes J, et al. Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv 2023; 7:1796.
  28. ImmunoCAP tryptase, Phadia AB, Uppsala, Sweden. http://www.phadia.com/en/Products/Allergy-testing-products/ImmunoCAP-Lab-Tests/ImmunoCAP-Tryptase (Accessed on April 02, 2018).
  29. http://www.accessdata.fda.gov/cdrh_docs/reviews/K103039.pdf (Accessed on March 15, 2016).
  30. Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14:190.
  31. Edston E, van Hage-Hamsten M. beta-Tryptase measurements post-mortem in anaphylactic deaths and in controls. Forensic Sci Int 1998; 93:135.
  32. Sahiner UM, Yavuz ST, Buyuktiryaki B, et al. Serum basal tryptase levels in healthy children: correlation between age and gender. Allergy Asthma Proc 2014; 35:404.
  33. Sverrild A, van der Sluis S, Kyvik KO, et al. Genetic factors account for most of the variation in serum tryptase--a twin study. Ann Allergy Asthma Immunol 2013; 111:286.
  34. Valent P, Hoermann G, Bonadonna P, et al. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT. J Allergy Clin Immunol Pract 2023; 11:3010.
  35. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157:215.
  36. Valent P, Akin C, Bonadonna P, et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract 2019; 7:1125.
  37. Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Int Arch Allergy Immunol 2019; 180:44.
  38. Baretto RL, Beck S, Heslegrave J, et al. Validation of international consensus equation for acute serum total tryptase in mast cell activation: A perioperative perspective. Allergy 2017; 72:2031.
  39. Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.
  40. Ruëff F, Przybilla B, Biló MB, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010; 126:105.
  41. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680.
  42. Zanotti R, Lombardo C, Passalacqua G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 2015; 136:135.
  43. Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract 2015; 3:350.
  44. Sordi B, Vanderwert F, Crupi F, et al. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis. J Allergy Clin Immunol 2023; 151:485.
  45. Polivka L, Madrange M, Bulai-Livideanu C, et al. Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes. J Allergy Clin Immunol 2024; 153:349.
  46. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.
  47. Yunginger JW, Nelson DR, Squillace DL, et al. Laboratory investigation of deaths due to anaphylaxis. J Forensic Sci 1991; 36:857.
  48. De Schryver S, Halbrich M, Clarke A, et al. Tryptase levels in children presenting with anaphylaxis: Temporal trends and associated factors. J Allergy Clin Immunol 2016; 137:1138.
  49. Mayer DE, Krauskopf A, Hemmer W, et al. Usefulness of post mortem determination of serum tryptase, histamine and diamine oxidase in the diagnosis of fatal anaphylaxis. Forensic Sci Int 2011; 212:96.
  50. Randall B, Butts J, Halsey JF. Elevated postmortem tryptase in the absence of anaphylaxis. J Forensic Sci 1995; 40:208.
  51. Bosso JV, Schwartz LB, Stevenson DD. Tryptase and histamine release during aspirin-induced respiratory reactions. J Allergy Clin Immunol 1991; 88:830.
  52. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94:1046.
  53. Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996; 26:807.
  54. Silvers WS, Essember LJ, Williams PB, et al. Anaphylaxis due to Diclofenac Sodium (Voltaren): Evidence of mast cell mediator release. Immunol Allergy Pract 1991; 13:193.
  55. The FO, Bennink RJ, Ankum WM, et al. Intestinal handling-induced mast cell activation and inflammation in human postoperative ileus. Gut 2008; 57:33.
  56. McLean-Tooke A, Goulding M, Bundell C, et al. Postmortem serum tryptase levels in anaphylactic and non-anaphylactic deaths. J Clin Pathol 2014; 67:134.
  57. Xiao N, Li DR, Wang Q, et al. Postmortem Serum Tryptase Levels with Special Regard to Acute Cardiac Deaths. J Forensic Sci 2017; 62:1336.
  58. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114:3.
  59. Carter MC, Desai A, Komarow HD, et al. A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. J Allergy Clin Immunol 2018; 141:180.
  60. Lyons JJ, Sun G, Stone KD, et al. Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol 2014; 133:1471.
  61. Sabato V, Chovanec J, Faber M, et al. First Identification of an Inherited TPSAB1 Quintuplication in a Patient with Clonal Mast Cell Disease. J Clin Immunol 2018; 38:457.
  62. Lyons JJ, Chovanec J, O'Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol 2021; 147:622.
  63. Boyden SE, Desai A, Cruse G, et al. Vibratory Urticaria Associated with a Missense Variant in ADGRE2. N Engl J Med 2016; 374:656.
  64. Nakamura Y, Kambe N, Saito M, et al. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med 2009; 206:1037.
  65. Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis 2017; 76:942.
  66. Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012; 366:330.
  67. Schussler E, Yang A, Lyons JJ, et al. Persistent tryptase elevation in a patient with Gaucher disease. J Allergy Clin Immunol Pract 2018; 6:697.
  68. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001; 98:2200.
  69. Sperr WR, Stehberger B, Wimazal F, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002; 43:1097.
  70. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660.
  71. Brezin AL, Brezin JH, Raible DG, et al. Elevated stem cell factor and a-protryptase levels in uremia. J Allergy Clin Immunol 1999; 103:S233 (Abstract).
  72. Dugas-Breit S, Schöpf P, Dugas M, et al. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges 2005; 3:343.
  73. Sirvent AE, González C, Enríquez R, et al. Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease. J Nephrol 2010; 23:282.
  74. Desai A, Sowerwine K, Liu Y, et al. GATA-2-deficient mast cells limit IgE-mediated immediate hypersensitivity reactions in human subjects. J Allergy Clin Immunol 2019; 144:613.
  75. Cooper PJ, Schwartz LB, Irani AM, et al. Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin. J Infect Dis 2002; 186:1307.
  76. Costa JJ, Demetri GD, Harrist TJ, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183:2681.
  77. Schliemann S, Seyfarth F, Hipler UC, Elsner P. Impact of age and heterophilic interference on the basal serum tryptase, a risk indication for anaphylaxis, in 1,092 dermatology patients. Acta Derm Venereol 2012; 92:484.
  78. Sargur R, Cowley D, Murng S, et al. Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assay. Clin Exp Immunol 2011; 163:339.
  79. van Toorenenbergen AW, van Daele PL, Boonstra JG. False-elevated serum tryptase assay result caused by heterophilic antibodies. J Allergy Clin Immunol 2005; 116:1159.
  80. van Toorenenbergen AW, Hooijkaas H, Heerenbrink GK, Dufour-van den Goorbergh DM. Heterophilic antibody interference in a tryptase immunoassay. Clin Biochem 2008; 41:331.
  81. Vitte J, Sabato V, Tacquard C, et al. Use and Interpretation of Acute and Baseline Tryptase in Perioperative Hypersensitivity and Anaphylaxis. J Allergy Clin Immunol Pract 2021; 9:2994.
  82. Salem A, Rozov S, Al-Samadi A, et al. Histamine metabolism and transport are deranged in human keratinocytes in oral lichen planus. Br J Dermatol 2017; 176:1213.
  83. Alcañiz L, Vega A, Chacón P, et al. Histamine production by human neutrophils. FASEB J 2013; 27:2902.
  84. Laroche D, Vergnaud MC, Dubois F, et al. Plasma histamine and tryptase during anaphylactoid reactions. Agents Actions 1992; 36:C201.
  85. Stephan V, Zimmermann A, Kühr J, Urbanek R. Determination of N-methylhistamine in urine as an indicator of histamine release in immediate allergic reactions. J Allergy Clin Immunol 1990; 86:862.
  86. Takeda J, Ueda E, Takahashi J, Fukushima K. Plasma N-methylhistamine concentration as an indicator of histamine release by intravenous d-tubocurarine in humans: preliminary study in five patients by radioimmunoassay kits. Anesth Analg 1995; 80:1015.
  87. Schulze S, Niggemann B, Savaser AN, Wahn U. Diurnal variation of urinary histamine and 1-methylhistamine excretion in healthy children. Allergy 1992; 47:644.
  88. Oosting E, Keyzer JJ, Wolthers BG, Scholtis RJ. Age dependent normal values of histamine and histamine metabolites in human urine. Agents Actions 1988; 23:307.
  89. Laroche D, Dubois F, Lefrançois C, et al. [Early biological markers of anaphylactoid reactions occurring during anesthesia]. Ann Fr Anesth Reanim 1992; 11:613.
  90. Reference laboratory services for healthcare organizations. http://www.mayomedicallaboratories.com/ (Accessed on March 15, 2016).
  91. Morrow JD, Margolies GR, Rowland J, Roberts LJ 2nd. Evidence that histamine is the causative toxin of scombroid-fish poisoning. N Engl J Med 1991; 324:716.
  92. Keyzer JJ, van Saene HK, van den Berg GA, Wolthers BG. Influence of decontamination of the digestive tract on the urinary excretion of histamine and some of its metabolites. Agents Actions 1984; 15:238.
  93. Keyzer JJ, Breukelman H, Wolthers BG, et al. Urinary excretion of histamine and some of its metabolites in man: influence of the diet. Agents Actions 1984; 15:189.
  94. Oosting E, Keyzer JJ, Wolthers BG. Correlation between urinary levels of histamine metabolites in 24-hour urine and morning urine samples of man: influence of histamine-rich food. Agents Actions 1989; 27:205.
  95. Hershko AY, Dranitzki Z, Ulmanski R, et al. Constitutive hyperhistaminaemia: a possible mechanism for recurrent anaphylaxis. Scand J Clin Lab Invest 2001; 61:449.
  96. Song WL, Stubbe J, Ricciotti E, et al. Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans. J Clin Invest 2012; 122:1459.
  97. Roberts LJ 2nd, Sweetman BJ, Lewis RA, et al. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980; 303:1400.
  98. Luna-Gomes T, Magalhães KG, Mesquita-Santos FP, et al. Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation. J Immunol 2011; 187:6518.
  99. Awad JA, Morrow JD, Roberts LJ 2nd. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol 1994; 93:817.
  100. Morrow JD, Guzzo C, Lazarus G, et al. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995; 104:937.
  101. Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 2008; 147:338.
  102. Higashi N, Mita H, Ono E, et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084.
  103. Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. J Allergy Clin Immunol Pract 2014; 2:775.
  104. Assays of urinary prostaglandins are available throught Mayo Medical Laboratories. www.mayomedicallaboratories.com (Accessed on October 20, 2014).
  105. Ono E, Taniguchi M, Mita H, et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy 2009; 39:72.
  106. Schwartz LB. Analysis of MC(T) and MC(TC) mast cells in tissue. Methods Mol Biol 2006; 315:53.
  107. Zhou X, Buckley MG, Lau LC, et al. Mast Cell Carboxypeptidase as a New Clinical Marker for Anaphylaxis. J Allergy Clin Immunol 2006; 117:S85.
  108. Brown TA, Whitworth HS, Zhou XY, et al. Mast cell carboxypeptidase as a confirmatory and predictive marker in allergic reactions to drugs. J Allergy Clin Immunol 2011; 127:Abstract 143.
  109. Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358:28.
  110. Perelman B, Adil A, Vadas P. Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy. Allergy Asthma Clin Immunol 2014; 10:20.
  111. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358:2457.
  112. Hakim RM, Breillatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984; 311:878.
  113. Stone SF, Isbister GK, Shahmy S, et al. Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine production and mast cell degranulation. PLoS Negl Trop Dis 2013; 7:e2326.
  114. Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 2008; 46:225.
  115. Moghimi SM, Farhangrazi ZS. Nanomedicine and the complement paradigm. Nanomedicine 2013; 9:458.
Topic 389 Version 20.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟